Chronic Lymphocytic Leukemia | Specialty

Resistance to Ibrutinib in CLL

January 4th 2019

Resistance to Venetoclax in CLL

January 4th 2019

CD20-Targeted Antibodies With Novel Agents for CLL

January 4th 2019

Toxicity Management With Venetoclax for CLL

January 4th 2019

Venetoclax + Rituximab in Relapsed CLL

January 4th 2019

Real-World Data for CLL

January 4th 2019

Emerging BTK Inhibitors for CLL

January 4th 2019

Prognostic Factors in CLL

January 4th 2019

Novel Combination Therapies for CLL

January 4th 2019

Ibrutinib Versus FCR for Younger Patients With CLL

January 4th 2019

First-Line Therapy for Older Patients With CLL

January 4th 2019

Dr. Lamanna Discusses the MURANO Trial in CLL

January 2nd 2019

Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.

Fixed-Duration Venetoclax Triplet Active in CLL

January 1st 2019

Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.

Dr. Seymour on Updated Findings From the MURANO Trial in CLL

December 12th 2018

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the updated findings from the MURANO trial presented at the 2018 ASH Annual Meeting.

Acalabrutinib Achieves High Response Rates in CLL

December 11th 2018

Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib, results of an open-label phase II trial showed.

Dr. Gauthier on Potential for CAR T Cells in CLL

December 11th 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL

December 5th 2018

The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.

Dr. Seymour on Role of Ibrutinib in CLL

December 4th 2018

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses the role of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Mutation in BCL2 Protein Confers Resistance to Venetoclax

December 4th 2018

A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.

High MRD-Negative Rates Seen with Venetoclax in Patients With Relapsed/Refractory CLL

December 4th 2018

Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.